Cargando…

Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study

BACKGROUND: In the 52-week ETHOS study (NCT02465567), fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) reduced moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations versus fixed-dose long-acting muscarinic antagonist (LAMA)/long-act...

Descripción completa

Detalles Bibliográficos
Autores principales: de Nigris, Enrico, Treharne, Catrin, Brighton, Nick, Holmgren, Ulf, Walker, Andrew, Haughney, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700475/
https://www.ncbi.nlm.nih.gov/pubmed/36444374
http://dx.doi.org/10.2147/COPD.S381138
_version_ 1784839319278583808
author de Nigris, Enrico
Treharne, Catrin
Brighton, Nick
Holmgren, Ulf
Walker, Andrew
Haughney, John
author_facet de Nigris, Enrico
Treharne, Catrin
Brighton, Nick
Holmgren, Ulf
Walker, Andrew
Haughney, John
author_sort de Nigris, Enrico
collection PubMed
description BACKGROUND: In the 52-week ETHOS study (NCT02465567), fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) reduced moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations versus fixed-dose long-acting muscarinic antagonist (LAMA)/long-acting β(2)-agonist (LABA) or inhaled corticosteroid (ICS)/LABA dual therapies. Here, ETHOS data were used to estimate the long-term cost-effectiveness of BGF versus LAMA/LABA and ICS/LABA dual therapies in the United Kingdom. METHODS: Costs, exacerbations, quality-adjusted life-years (QALYs), and LYs were extrapolated using a Markov model that considered disease severity progression, risk of moderate and severe exacerbations, adverse events, and treatment discontinuation in patients with moderate-to-very severe COPD receiving BGF 320/14.4/10 µg, the LAMA/LABA glycopyrronium/formoterol fumarate dihydrate 14.4/10 µg (GFF), or the ICS/LABA budesonide/formoterol fumarate dihydrate 320/10 µg (BFF). Utilities for COPD severity states were estimated using EuroQol 5-dimension 5-level data from ETHOS. Exacerbation disutilities were sourced from published literature. Healthcare resource utilization was based on ETHOS data, published literature, key external experts’ input, and informed assumptions. Unit costs came from the UK National Health Service Schedule of Reference Costs, Unit Costs of Health and Social Care from the Personal Social Services Research Unit, and published literature. A lifetime horizon was considered, with costs, QALYs, and LYs discounted at 3.5% per annum. RESULTS: The incremental cost–utility ratio (ICUR; per QALY gained) was £9901 for BGF versus GFF and £2164 for BGF versus BFF. The probability of treatments being cost-effective at the conventional UK-adopted willingness-to-pay threshold of ICUR <£20,000 was 85.1% for BGF, 14.3% for GFF, and 0.6% for BFF. CONCLUSION: Based on ETHOS data, BGF was demonstrated to be cost-effective versus LAMA/LABA and ICS/LABA dual therapies at the conventional UK-adopted willingness-to-pay threshold (ICUR <£20,000). The main cost-effectiveness driver for BGF versus LAMA/LABA and ICS/LABA therapies was reduction in rate of exacerbations, which reduced costs and preserved quality of life.
format Online
Article
Text
id pubmed-9700475
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97004752022-11-27 Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study de Nigris, Enrico Treharne, Catrin Brighton, Nick Holmgren, Ulf Walker, Andrew Haughney, John Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: In the 52-week ETHOS study (NCT02465567), fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) reduced moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations versus fixed-dose long-acting muscarinic antagonist (LAMA)/long-acting β(2)-agonist (LABA) or inhaled corticosteroid (ICS)/LABA dual therapies. Here, ETHOS data were used to estimate the long-term cost-effectiveness of BGF versus LAMA/LABA and ICS/LABA dual therapies in the United Kingdom. METHODS: Costs, exacerbations, quality-adjusted life-years (QALYs), and LYs were extrapolated using a Markov model that considered disease severity progression, risk of moderate and severe exacerbations, adverse events, and treatment discontinuation in patients with moderate-to-very severe COPD receiving BGF 320/14.4/10 µg, the LAMA/LABA glycopyrronium/formoterol fumarate dihydrate 14.4/10 µg (GFF), or the ICS/LABA budesonide/formoterol fumarate dihydrate 320/10 µg (BFF). Utilities for COPD severity states were estimated using EuroQol 5-dimension 5-level data from ETHOS. Exacerbation disutilities were sourced from published literature. Healthcare resource utilization was based on ETHOS data, published literature, key external experts’ input, and informed assumptions. Unit costs came from the UK National Health Service Schedule of Reference Costs, Unit Costs of Health and Social Care from the Personal Social Services Research Unit, and published literature. A lifetime horizon was considered, with costs, QALYs, and LYs discounted at 3.5% per annum. RESULTS: The incremental cost–utility ratio (ICUR; per QALY gained) was £9901 for BGF versus GFF and £2164 for BGF versus BFF. The probability of treatments being cost-effective at the conventional UK-adopted willingness-to-pay threshold of ICUR <£20,000 was 85.1% for BGF, 14.3% for GFF, and 0.6% for BFF. CONCLUSION: Based on ETHOS data, BGF was demonstrated to be cost-effective versus LAMA/LABA and ICS/LABA dual therapies at the conventional UK-adopted willingness-to-pay threshold (ICUR <£20,000). The main cost-effectiveness driver for BGF versus LAMA/LABA and ICS/LABA therapies was reduction in rate of exacerbations, which reduced costs and preserved quality of life. Dove 2022-11-22 /pmc/articles/PMC9700475/ /pubmed/36444374 http://dx.doi.org/10.2147/COPD.S381138 Text en © 2022 de Nigris et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
de Nigris, Enrico
Treharne, Catrin
Brighton, Nick
Holmgren, Ulf
Walker, Andrew
Haughney, John
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
title Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
title_full Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
title_fullStr Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
title_full_unstemmed Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
title_short Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
title_sort cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: united kingdom analysis using the ethos study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700475/
https://www.ncbi.nlm.nih.gov/pubmed/36444374
http://dx.doi.org/10.2147/COPD.S381138
work_keys_str_mv AT denigrisenrico costeffectivenessoftripletherapywithbudesonideglycopyrroniumformoterolfumaratedihydrateversusdualtherapiesinmoderatetoveryseverechronicobstructivepulmonarydiseaseunitedkingdomanalysisusingtheethosstudy
AT treharnecatrin costeffectivenessoftripletherapywithbudesonideglycopyrroniumformoterolfumaratedihydrateversusdualtherapiesinmoderatetoveryseverechronicobstructivepulmonarydiseaseunitedkingdomanalysisusingtheethosstudy
AT brightonnick costeffectivenessoftripletherapywithbudesonideglycopyrroniumformoterolfumaratedihydrateversusdualtherapiesinmoderatetoveryseverechronicobstructivepulmonarydiseaseunitedkingdomanalysisusingtheethosstudy
AT holmgrenulf costeffectivenessoftripletherapywithbudesonideglycopyrroniumformoterolfumaratedihydrateversusdualtherapiesinmoderatetoveryseverechronicobstructivepulmonarydiseaseunitedkingdomanalysisusingtheethosstudy
AT walkerandrew costeffectivenessoftripletherapywithbudesonideglycopyrroniumformoterolfumaratedihydrateversusdualtherapiesinmoderatetoveryseverechronicobstructivepulmonarydiseaseunitedkingdomanalysisusingtheethosstudy
AT haughneyjohn costeffectivenessoftripletherapywithbudesonideglycopyrroniumformoterolfumaratedihydrateversusdualtherapiesinmoderatetoveryseverechronicobstructivepulmonarydiseaseunitedkingdomanalysisusingtheethosstudy